CGT1815 / Cogent Biosci - LARVOL DELTA

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones… (GlobeNewswire) - "Submit Investigational New Drug (IND) applications for CGT1815, Cogent’s novel, selective pan-KRAS(ON) inhibitor and CGT1145, Cogent’s novel, selective JAK2 V617F inhibitor; Present clinical data on CGT4859, Cogent’s selective and potent FGFR 2/3 inhibitor, from its Phase 1/2 study in patients with alterations in FGFR2 or FGFR3; Complete dose escalation for both CGT4255, Cogent’s CNS-penetrant, selective mutant ErbB2 inhibitor, and CGT6297, Cogent’s selective PI3Kα inhibitor."

IND • P1/2 data • Trial status • Breast Cancer • Cholangiocarcinoma • Lung Cancer